Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
to evaluate the pharmacokinetics, and pharmacodynamics of a single dose of Tai Ai injection in healthy adult Chinese subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tai Ai(RC18) 80mg | Experimental | ·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18 |
|
| Tai Ai(RC18) 160mg | Experimental | ·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18 |
|
| RC18 240mg | Experimental | ·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tai Ai(RC18) 80mg | Biological | The patient received one treatment of RC18 80mg in the test group |
|
| Measure | Description | Time Frame |
|---|---|---|
| C-max | Maximum observed plasma concentration | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| T-max | Time to reach maximum observed plasma concentration | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| T1/2 | apparent terminal half-life | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| AUC0-t | area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| AUC0-∞ | Area under the plasma concentration-time curve from time 0 extrapolated to infinity | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of AEs (adverse events).Through observing number of total AEs and number of subjects with AEs and other factors of AEs ,to evaluate the safety and tolerance of healthy subjects. | Occurrence of all adverse events from signing of informed consent through end of study treatment. | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zhijun Li, M.D. | The First Affiliated Hospital of Bengbu Medical University | Principal Investigator |
| Huan Zhou, M.D. | The First Affiliated Hospital of Bengbu Medical University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Remegen,ltd. | Yantai | Shandong | 264006 | China |
Not provided
| ID | Term |
|---|---|
| C035529 | RC-18 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tai Ai(RC18) 160mg | Biological | The patient received one treatment of RC18 160mg in the test group |
|
| RC18 240mg | Biological | The patient received one treatment of RC18 240mg in the test group |
|
| Evaluation of Vital Signs | Through observing the normal and abnormal conditions of axillary temperature to evaluate the safety and tolerance of healthy subjects. Axillary temperature's normal :≥36 and ≤37°C. Clinical significance of abnormal values as judged by the investigator | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| Evaluation of Vital Signs | Through observing the normal and abnormal conditions of Pulse rate to evaluate the safety and tolerance of healthy subjects. Pulse rate's normal :≥60 and ≤100. Clinical significance of abnormal values as judged by the investigator | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| Evaluation of Vital Signs | Through observing the normal and abnormal conditions of Blood pressure (both systolic and diastolic) to evaluate the safety and tolerance of healthy subjects. systolic pressure 's normal: ≥90 and ≤139 ; diastolic pressure's normal :≥60 and ≤89. Clinical significance of abnormal values as judged by the investigator | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |
| Evaluation of Vital Signs | Through observing the normal and abnormal conditions of respiration to evaluate the safety and tolerance of healthy subjects. respiration's normal :≥10 and ≤24. Clinical significance of abnormal values as judged by the investigator | Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57 |